KR920703081A - 자기항원의 에어로졸 투여에 의한 자기면역질환의 개선된 치료방법 - Google Patents
자기항원의 에어로졸 투여에 의한 자기면역질환의 개선된 치료방법Info
- Publication number
- KR920703081A KR920703081A KR1019920701486A KR920701486A KR920703081A KR 920703081 A KR920703081 A KR 920703081A KR 1019920701486 A KR1019920701486 A KR 1019920701486A KR 920701486 A KR920701486 A KR 920701486A KR 920703081 A KR920703081 A KR 920703081A
- Authority
- KR
- South Korea
- Prior art keywords
- autoantigen
- autoimmune disease
- autoimmune
- disease
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Marine Sciences & Fisheries (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rehabilitation Therapy (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
내용 없음
Description
자기항원의 에어로졸 투여에 의한 자기면역질환의 개선된 치료방법
[도면의 간단한 설명]
제1도는 여러농도로 경구투여된 MBP가 EAE의 경과 및 위중도에 미치는 질병억압효과를 도시한 그래프임.
제2도는 여러농도로 에어로졸 형태로 투여된 MBP가 EAE의 경과 및 위중도에 미치는 질병억압효과를 도시한 그래프임.
제3(a-d)도는 GP-MBP를 경구 또는 에어로졸 형태로 투여한 경우 EAE의 경과 및 위중도에 미치는 여러가지 투여량의 효과를 직접 비교한 일련의 그래프임.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (18)
- 자기면역질환에 특이적으로 지향된 자기항원, 상기 자기항원의 자기면역질환 억압단편 및 상기 자기항원의 동족체중에서 선택된 한가지 이상을 상기 자기면역질환의 예방 또는 치료 유효량으로 하여 에어로졸 형태로서 자기면역질환에 걸린 포유동물에게 투여하는 것으로 됨을 특징으로 하는 포유동물에 있어서의 자기면역질환의 치료 또는 이의 발병을 예방하는 방법.
- 제1항에 있어서, 자기항원의 미엘린 염기성 단백질인 것이 특징인 방법.
- 제1항에 있어서, 자기항원이 클라겐인 것이 특징인 방법.
- 제1항에 있어서, 자기면역질환이 다발성 경화증인 것이 특징인 방법.
- 제1항에 있어서, 자기면역질환이 류마치스성 관절염인 것이 특징인 방법.
- 자기항원, 이 자기항원의 자기면역질환 억압단편 및 이 자기항원의 동족체중에서 선택된 한가지 이상을 상기 자기면역질환의 치료에 유효한 양으로 함유하는, 자기면역질환에 걸린 포유동물을 치료하기 위한 에어로졸 형태의 약리적 제제.
- 제6항에 있어서, 자기항원이 미엘린 염기성 단백질인 것이 특징인 제제.
- 제6항에 있어서, 자기항원이 콜라겐인 것이 특징인 제제.
- 제6항에 있어서, 자기항원이 미엘린 염기성 단백질의 자기면역질 환-억압단편인 것이 특징인 제제.
- 제6항에 있어서, 제약상 허용되는 담체 또는 희석제를 추가로 함유하는 것이 특징인 제제.
- 제6항에 있어서, 자기면역질환이 다발성 경화증인 것이 특징인 제제.
- 제6항에 있어서, 자기면역질환이 류마치스성 관절염인 것이 특징인 제제.
- 다발성 경화증 증상을 보이는 자기면역질환에 걸린 포유동물의 치료방법에 있어서, 상기 자기면역질환에 특이적인 자기항원, 상기 자기항원의 자기면역질환 억압단편 및 상기 자기항원의 동족체중에서 선택된 한가지 이상의 물질의 상기 질환억압 유효량을 에어로졸 형태로 하여 폐로(pulmonarytract)를 통해 상기 포유동물에게 투여하는 것으로 됨을 특징으로 하는 방법.
- 제13항에 있어서, 상기 자기항원이 미엘린 염기성 단백질인 것이 특징인 방법.
- 관절염 증상을 보이는 자기면역질환의 치료방법에 있어서, 상기 자기면역질환에 특이적인 자기항원, 상기 자기항원의 자기면역질환 억압단편 및 상기 자기항원의 동족체중에서 선택된 한가지 이상의 물질의 상기 질환억압 유효량을 에어로졸 형태로 투여하는 것을 특징으로 하는 방법.
- 제15항에 있어서, 상기 자기항원이 콜라겐인 것이 특징인 방법.
- 자기면역질환에 걸린 포유동물의 치료방법에 있어서, 자기면역질환에 특이적인 자기항원, 상기 자기항원의 자기면역질환 억압단편 및 상기 자기항원의 동족체중에서 선택된 한가지 이상의 물질을 함유하는 미세하게 분할된 스프레이의 상기 질환억압 유효량을 에어로졸 형태로 하여 상기 포유동물에게 폐로를 통해 공급하는 것으로 됨을 특징으로 하는 방법.
- 자기면역질환에 특이적인 자기항원, 상기 자기항원의 자기면역질환 억압단편 및 상기 자기항원의 동족체 중에서 선택된 한가지 이상의 물질을 함유하는 수성 에어로졸을 상기 자기면역질환 치료에 유효한 양으로 함유하는 약리적 제제.※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45480689A | 1989-12-20 | 1989-12-20 | |
US454,806 | 1989-12-20 | ||
PCT/US1990/007455 WO1991008760A1 (en) | 1989-12-20 | 1990-12-17 | Improved treatment of autoimmune diseases by aerosol administration of auto antigens |
Publications (2)
Publication Number | Publication Date |
---|---|
KR920703081A true KR920703081A (ko) | 1992-12-17 |
KR0185747B1 KR0185747B1 (ko) | 1999-05-01 |
Family
ID=23806184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920701486A KR0185747B1 (ko) | 1989-12-20 | 1990-12-17 | 자기항원의 에어로졸 투여에 의한 자기면역질환의 개선된 치료방법 |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0506785B1 (ko) |
JP (1) | JP2625253B2 (ko) |
KR (1) | KR0185747B1 (ko) |
AT (1) | ATE190496T1 (ko) |
AU (1) | AU642693B2 (ko) |
BR (1) | BR9007950A (ko) |
CA (1) | CA2070281C (ko) |
DE (1) | DE69033487T2 (ko) |
DK (1) | DK0506785T3 (ko) |
ES (1) | ES2144398T3 (ko) |
GR (1) | GR3033634T3 (ko) |
HU (2) | HUT61487A (ko) |
IL (1) | IL96734A (ko) |
WO (1) | WO1991008760A1 (ko) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869054A (en) * | 1987-06-24 | 1999-02-09 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of autoantigens |
US6645504B1 (en) | 1987-06-24 | 2003-11-11 | Autoimmune Inc. | Bystander suppression of type I diabetes by oral administration of glucagon |
US5849298A (en) * | 1987-06-24 | 1998-12-15 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of bovine myelin |
US5843445A (en) * | 1987-06-24 | 1998-12-01 | Autoimmune, Inc. | Method of treating rheumatoid arthritis with type II collagen |
CA2063416C (en) * | 1989-07-14 | 2000-05-30 | The United States Government Represented By The Secretary Of The Departm Ent Of Health And Human Services | Methods of treating or preventing autoimmune uveoretinitis mammals |
IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
ATE319474T1 (de) * | 1990-10-15 | 2006-03-15 | Autoimmune Inc | Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen |
WO1993016724A1 (en) * | 1992-02-28 | 1993-09-02 | Autoimmune, Inc. | Bystander suppression of autoimmune diseases |
JP3845447B2 (ja) * | 1992-09-25 | 2006-11-15 | オートイミューン インク | タイプ▲ii▼コラーゲンによるリウマチ性関節炎治療方法 |
WO1994027634A1 (en) * | 1993-06-02 | 1994-12-08 | Institute For Child Health Research | Cryptic peptides for use in inducing immunologic tolerance |
PL324091A1 (en) * | 1994-10-25 | 1998-05-11 | Immulogic Pharma Corp | Compositions and procedure for treating sclerosis multiplex |
US6488933B2 (en) | 1995-07-05 | 2002-12-03 | Yeda Research And Development Co. Ltd. | Preparations for the treatment of T cell mediated diseases |
US5856446A (en) * | 1995-07-07 | 1999-01-05 | Autoimmune Inc. | Method of treating rheumatoid arthritis with low dose type II collagen |
CA2238439C (en) * | 1996-01-05 | 2004-11-30 | Autoimmune, Inc. | Method for preparation of type ii collagen |
AUPO269996A0 (en) * | 1996-10-01 | 1996-10-24 | Walter And Eliza Hall Institute Of Medical Research, The | A method of prophylaxis and treatment |
US6471943B1 (en) | 1996-12-30 | 2002-10-29 | Battelle Pulmonary Therapeutics, Inc. | Formulation and method for treating neoplasms by inhalation |
US7097845B2 (en) | 1997-04-23 | 2006-08-29 | Jacob Sten Petersen | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
SE9902155L (sv) * | 1999-06-09 | 2000-12-10 | Bjoern Rydevik | Serum antibodies |
ES2292594T3 (es) | 2000-05-24 | 2008-03-16 | The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services | E-selectina para tratar o prevenir accidentes cerebrovasculares. |
US7897575B2 (en) | 2000-05-24 | 2011-03-01 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment and prevention of vascular dementia |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
DE10230381A1 (de) | 2002-07-05 | 2004-01-22 | Institut für Medizintechnologie Magdeburg GmbH, IMTM | Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen |
CA2498651C (en) | 2002-09-13 | 2011-08-30 | Universite Laval | Nucleoside triphosphate diphosphohydrolase and uses thereof |
TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
TW200635607A (en) | 2004-12-15 | 2006-10-16 | Elan Pharm Inc | Humanized Aβ antibodies for use in improving cognition |
CN101365714A (zh) | 2005-07-01 | 2009-02-11 | 福赛特儿童口腔医院 | 结核抗原的检测分析及疫苗 |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
ES2498040T3 (es) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
US20130236484A1 (en) | 2012-03-08 | 2013-09-12 | Detectogen Inc. | Leishmaniasis antigen detection assays and vaccines |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US379778A (en) * | 1888-03-20 | Machine for mitering printers rules | ||
US65734A (en) * | 1867-06-11 | Joseph fantou | ||
DE3856566T2 (de) * | 1987-06-24 | 2004-06-24 | Brigham And Women's Hospital, Boston | Behandlung von Autoimmun-Erkrankungen durch orale Verabreichung von Autoantigenen |
EP0408649A4 (en) * | 1988-04-08 | 1991-11-27 | Genetics Institute, Inc. | Bone and cartilage inductive compositions |
-
1990
- 1990-12-17 AT AT91901622T patent/ATE190496T1/de not_active IP Right Cessation
- 1990-12-17 KR KR1019920701486A patent/KR0185747B1/ko not_active IP Right Cessation
- 1990-12-17 JP JP3501992A patent/JP2625253B2/ja not_active Expired - Fee Related
- 1990-12-17 ES ES91901622T patent/ES2144398T3/es not_active Expired - Lifetime
- 1990-12-17 CA CA002070281A patent/CA2070281C/en not_active Expired - Lifetime
- 1990-12-17 HU HU922072A patent/HUT61487A/hu unknown
- 1990-12-17 WO PCT/US1990/007455 patent/WO1991008760A1/en active IP Right Grant
- 1990-12-17 EP EP91901622A patent/EP0506785B1/en not_active Expired - Lifetime
- 1990-12-17 DE DE69033487T patent/DE69033487T2/de not_active Expired - Lifetime
- 1990-12-17 AU AU69791/91A patent/AU642693B2/en not_active Expired
- 1990-12-17 DK DK91901622T patent/DK0506785T3/da active
- 1990-12-17 BR BR909007950A patent/BR9007950A/pt not_active Application Discontinuation
- 1990-12-20 IL IL9673490A patent/IL96734A/en not_active IP Right Cessation
-
1995
- 1995-02-15 HU HU95P/P00074P patent/HU210715A9/hu unknown
-
2000
- 2000-06-08 GR GR20000401321T patent/GR3033634T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP0506785A1 (en) | 1992-10-07 |
ATE190496T1 (de) | 2000-04-15 |
JPH05504341A (ja) | 1993-07-08 |
HU9202072D0 (en) | 1992-09-28 |
DE69033487T2 (de) | 2000-06-29 |
WO1991008760A1 (en) | 1991-06-27 |
DK0506785T3 (da) | 2000-07-24 |
CA2070281C (en) | 2005-08-23 |
GR3033634T3 (en) | 2000-10-31 |
CA2070281A1 (en) | 1991-06-21 |
BR9007950A (pt) | 1992-10-27 |
EP0506785A4 (en) | 1993-09-08 |
DE69033487D1 (de) | 2000-04-20 |
EP0506785B1 (en) | 2000-03-15 |
HU210715A9 (en) | 1995-06-28 |
ES2144398T3 (es) | 2000-06-16 |
AU642693B2 (en) | 1993-10-28 |
IL96734A0 (en) | 1991-09-16 |
HUT61487A (en) | 1993-01-28 |
IL96734A (en) | 1996-11-14 |
JP2625253B2 (ja) | 1997-07-02 |
AU6979191A (en) | 1991-07-18 |
KR0185747B1 (ko) | 1999-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR920703081A (ko) | 자기항원의 에어로졸 투여에 의한 자기면역질환의 개선된 치료방법 | |
NO931267D0 (no) | Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin | |
BR9814499A (pt) | Peptìdeo amida opióide sintético ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, processo para tratamento compreendendo a administração de uma quantidade da mesma | |
KR950002785A (ko) | 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜 | |
ES2179190T3 (es) | Inhalador dosificador para propianato de fluticasona. | |
BR9808786A (pt) | Composto peptìdio cìclico ou um seu sal ou pró-medicamento farmaceuticamente aceitáveis, composição farmacêutica, e, processos para tratar doenças associadas com a regulagem do cálcio em um paciente e para tratar a osteopenia ou a osteoporose em um mamìfero hospedeiro | |
MX9305070A (es) | Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1 | |
RU94041223A (ru) | Средство для лечения мотонейроновых заболеваний | |
ATE157257T1 (de) | Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen | |
BR9713141A (pt) | Composição farmcêutica processo e kit para o tratamento ou a prevenção de um quadro fisiológico asociado com um distúrbio isquêmico relacionado com trombose e um paciente, uso de quantidades farmaceuticamente efetivas de um composto com atividade anti-xa e de um composto antagonista de agregação de plaquetas, produto contendo estes compostos, e, uso destes compostos. | |
BR9007527A (pt) | Metodo para tratar ou prevenir a manifestacao clinica de uma doenca tendo os sintomas de uveoretinite e formulacao farmaceutica para tratar mamiferos sofrendo de uveoretinite | |
BR9809678A (pt) | Derivados de triptolìdeo úteis no tratamento de doenças autoimunes | |
RU94045866A (ru) | Применение бисфенилалкилпиперазинов для лечения расстройств, вызванных злоупотреблением веществами, способ лечения | |
KR910019623A (ko) | 상승병용을 이용한 안고혈압 치료 | |
BR9611671A (pt) | Método de alvejamento de dosagens de medicamentos e de agentes terapêuticos e de outros glicosaminoglicanos (gags) para tratar de uma doença ou condição em um ser humano. | |
BR0208920A (pt) | Inibidor de aromatase em dose única para tratamento de infertilidade | |
AR007059A1 (es) | Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto | |
KR880009656A (ko) | 국소 치근막 질환의 치료 또는 예방법 | |
Romano et al. | Delayed hypersensitivity to stepronin: a case report. | |
KR910700263A (ko) | 시클로리노펩티드를 포함하는 의약 | |
ES2101311T3 (es) | Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer. | |
KR890701111A (ko) | 사람의 이상지혈증의 치료방법 | |
KR900700126A (ko) | 췌장(膵腸) 질환등의 예방.치료제 | |
MANDAL et al. | BLOOD CHOLINESTERASE ACTIVITY IN ALBlNO RATS FOLLOWING HIGH DOSES OF TETRACYCLINE, CHLORAMPHENICOL AND TRIMETHOPRIM | |
KR910005856A (ko) | 호흡기 질환 치료용 제약 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20091016 Year of fee payment: 12 |
|
EXPY | Expiration of term |